Glumetza Settlements Worth $454 Million Get Initial Court Nod

Bulk buyers of the diabetes drug Glumetza won preliminary approval from a federal judge in San Francisco for settlements worth $454 million resolving claims that Bausch Health Cos., Lupin Ltd., and Assertio Therapeutics Inc. delayed the rollout of generic versions.

Judge William Alsup signed off tentatively Wednesday on the trio of deals disclosed over the previous two weeks in the U.S. District Court for the Northern District of California, canceling a class action antitrust trial that was set to start Oct. 4.

The agreements with “direct purchasers” of Glumetza call for payments of $300 million by Bausch, $150 ...